Health Condition 1: E11- Type 2 diabetes mellitus
Conditions
Interventions
Intervention1: Canagliflozin containing treatment regimen: No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagli
Sponsors
Johnson and Johnson Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: T2DM participants on a stable anti-hyperglycemic regimen containing one or more anti-diabetic drug for at least 30 days and had HbA1c of more than 7 percent at the time of, or within 2 weeks before canagliflozin 300 mg initiation T2DM participants as confirmed from hospital records T2DM participant having BMI greater than 25kg/m2 at the time of canagliflozin 300 mg initiation Participants having clinical assessment data (at least glycated haemoglobin A1c [HbA1c] and body weight) for at least two visits, that is (i.e.) visit at which treatment with canagliflozin 300 mg was initiated or 2 weeks before initiation and follow-up visit at 12 weeks (+-4 weeks) from initiation, in accordance with the usual clinical practice
Exclusion criteria
Exclusion criteria: Participants with history of autoimmune diabetes (type 1 diabetes mellitus [T1DM] or latent autoimmune diabetes in adults [LADA]), pancreas or betacell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or gestational diabetes or any off-label use or patient data refusal based on physician discretion Participants with a history of use of other Sodium Glucose co-Transporter 2 (SGLT2) inhibitor within 12 weeks (empagliflozin or dapagliflozin)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change From Baseline in Mean Hemoglobin A1c (HbA1c) Change in mean HbA1c from baseline to 12 weeks will be determined. HbA1c refers to glycated haemoglobin (A1c), which identifies average plasma glucose concentration. Change From Baseline in Mean Weight Change in mean body weight from baseline to 12 weeks will be determinedTimepoint: Baseline up to 12 weeks Baseline up to 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactDr Prashant Narang
Johnson and Johnson Private Limited
Outcome results
None listed